98%
921
2 minutes
20
Download full-text PDF |
Source |
---|
Zoonoses Public Health
September 2025
Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Introduction: Pigeon paramyxovirus type 1 (PPMV-1) is an antigenic variant of Avian Orthoavulavirus 1 (AOAV-1) (Newcastle disease virus) with a global distribution that causes lethal infections in pigeon and dove species. AOAV-1's infecting humans normally cause mild, self-limiting conjunctivitis, but since 2003, PPMV-1 has been associated with an increased number of severe and lethal respiratory and neurological infections in immunocompromised persons in the Netherlands, the USA, France, China and Australia.
Methods: PPMV-1's isolated from free-living pigeons and doves across South Africa from 2012 to 2024 were sequenced using conventional or next generation technologies.
Anat Sci Educ
September 2025
Human Anatomy, Vita-Salute San Raffaele University, Milan, Italy.
As emerging technologies reshape both the body and how we represent it, anatomical education stands at a threshold. Virtual dissection tools, AI-generated images, and immersive platforms are redefining how students learn anatomy, while real-world bodies are becoming hybridized through implants, neural interfaces, and bioengineered components. This Viewpoint explores what it means to teach human anatomy when the body is no longer entirely natural, and the image is no longer entirely real.
View Article and Find Full Text PDFJ Neuroimaging
September 2025
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Background And Purpose: Socioeconomic determinants of health impact childhood development and adult health outcomes. One key aspect is the physical environment and neighborhood where children live and grow. Emerging evidence suggests that neighborhood deprivation, often measured by the Area Deprivation Index (ADI), may influence neurodevelopment, but longitudinal and multimodal neuroimaging analyses remain limited.
View Article and Find Full Text PDFObesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
Eur Geriatr Med
September 2025
Department of Social Science, Center for Gerontology and Social Science, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Purpose: To investigate the longitudinal association between chronic pain and decline in activity of daily living (ADL) among community-dwelling older adults aged ≥ 60 years.
Methods: In this systematic review of prospective longitudinal studies with narrative synthesis, a comprehensive literature search was conducted using PubMed and Embase using free-text words and MeSH terms on February 3, 2025. Longitudinal studies that quantitatively assessed ADL at two or more time points and pain at least once were included.